Computed tomography
(CT) and magnetic resonance imaging (MRI) are
among the most well-established modalities in the field of noninvasive
medical imaging. Despite being powerful tools, both suffer from a
number of limitations and often fall short when it comes to full delineation
of pathological tissues. Since its conception, molecular imaging has
been commonly utilized to further the understanding of disease progression,
as well as monitor treatment efficacy. This has naturally led to the
advancement of the field of targeted imaging. Targeted imaging research
is currently dominated by ligand-modified contrast media for applications
in MRI and CT imaging. Although a plethora of targeting ligands exist,
a fine balance between their size and target binding efficiency must
be considered. This review will focus on aptamer- and peptide-modified
contrast agents, outlining selected formulations developed in recent
years while highlighting the advantages offered by these targeting
ligands.